Abstract
In recent years, Aβ aggregation prevention, one of the most concerned strategies in drug development has been carefully assessed to treat Alzheimer’s disease. Aβ peptides can transform structurally from random coil monomer into β-stranded protofibril via multiple oligomeric states. Among the various Aβ species, the identification of binding targets has been challenging due to the heterogeneity and metastable nature. A better understanding of Aβ species’ assembly details and structural properties has been more characterized recently. Numerous potential inhibitors have been identified that they can effectively bind to different Aβ species such as monomer, oligomer or protofibril during the inhibition of Aβ aggregation process. This review highlights the diversity of structural ensembles of Aβ species, from monomer to protofibril forms and the specific binding targets by their potential inhibitors. Comprehending the binding mechanism of Aβ inhibitors is indispensable for searching novel drug candidates against early-stage Alzheimer’s disease.
Keywords: Alzheimer's disease, Aβ species, conformational structure, Aβ inhibitors, computational approach, molecular simulations.
Current Pharmaceutical Design
Title:Understanding the Binding Mechanism of Amyloid-β Inhibitors from Molecular Simulations
Volume: 24 Issue: 28
Author(s): Linh Tran*
Affiliation:
- Computational Chemistry Research Group, Ton Duc Thang University, Ho Chi Minh, City,Vietnam
Keywords: Alzheimer's disease, Aβ species, conformational structure, Aβ inhibitors, computational approach, molecular simulations.
Abstract: In recent years, Aβ aggregation prevention, one of the most concerned strategies in drug development has been carefully assessed to treat Alzheimer’s disease. Aβ peptides can transform structurally from random coil monomer into β-stranded protofibril via multiple oligomeric states. Among the various Aβ species, the identification of binding targets has been challenging due to the heterogeneity and metastable nature. A better understanding of Aβ species’ assembly details and structural properties has been more characterized recently. Numerous potential inhibitors have been identified that they can effectively bind to different Aβ species such as monomer, oligomer or protofibril during the inhibition of Aβ aggregation process. This review highlights the diversity of structural ensembles of Aβ species, from monomer to protofibril forms and the specific binding targets by their potential inhibitors. Comprehending the binding mechanism of Aβ inhibitors is indispensable for searching novel drug candidates against early-stage Alzheimer’s disease.
Export Options
About this article
Cite this article as:
Tran Linh *, Understanding the Binding Mechanism of Amyloid-β Inhibitors from Molecular Simulations, Current Pharmaceutical Design 2018; 24 (28) . https://dx.doi.org/10.2174/1381612824666180813093420
DOI https://dx.doi.org/10.2174/1381612824666180813093420 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cathepsin D as a Promising Target for the Discovery of Novel Anticancer Agents
Current Cancer Drug Targets Editorial [Hot topic: Adenosine Receptor Ligands: Where Are We, and Where Are We Going? (Guest Editors: Tiziano Tuccinardi and Adriano Martinelli)]
Current Topics in Medicinal Chemistry Advances in Therapy for Psoriasis: An Overview of Infliximab, Etanercept, Efalizumab, Alefacept, Adalimumab, Tazarotene, and Pimecrolimus
Current Pharmaceutical Design Hydroxypyridinone Derivatives: A Fascinating Class of Chelators with Therapeutic Applications - An Update
Current Medicinal Chemistry Oligomeric Amyloid β -Protein as a Therapeutic Target in Alzheimers Disease: Its Significance Based on its Distinct Localization and the Occurrence of a Familial Variant Form
Current Alzheimer Research Alzheimer's disease: Targeting the Cholinergic System
Current Neuropharmacology Pathways by Which Aβ Facilitates Tau Pathology
Current Alzheimer Research Advances in Spirocyclic Hybrids: Chemistry and Medicinal Actions
Current Medicinal Chemistry Justification for Domestic Violence and Women’s Autonomy in Zambia
Applied Clinical Research, Clinical Trials and Regulatory Affairs The Efficacy of Stepped Care Models Involving Psychosocial Treatment of Alcohol Use Disorders and Nicotine Dependence: A Systematic Review of the Literature
Current Drug Abuse Reviews Methods to Profile the Macromolecular Targets of Small Compounds
Current Topics in Medicinal Chemistry Connection between JAK/STAT and PPARγ Signaling During the Progression of Multiple Sclerosis: Insights into the Modulation of T-Cells and Immune Responses in the Brain
Current Molecular Pharmacology Probing Cerebrovascular Alterations in Alzheimers Disease Using MRI: From Transgenic Models to Patients
Current Medical Imaging Infantile Epileptic Encephalopathy with Hypsarrhythmia (Infantile Spasms/West Syndrome) and Immunity
Central Nervous System Agents in Medicinal Chemistry Management of Spasticity in Progressive Multiple Sclerosis: Efficacy of Repeated Intrathecal Triamcinolone Acetonide Administration
Current Pharmaceutical Design Commentary
CNS & Neurological Disorders - Drug Targets Wavelet Transform Based Algorithm for Automatic Detection of Patient- Specific Single Spike-and-Wave Discharges in Simulated Real-Time Conditions
Neuroscience and Biomedical Engineering (Discontinued) KCa3.1 Channels and Glioblastoma: In Vitro Studies
Current Neuropharmacology Need for Nutritious Convenience Foods for the Elderly Population: A Review
Current Nutrition & Food Science Gene Frequency of <i>CYP2D6*4</i> and <i>*10</i> Variants in Karachi Population
Current Pharmacogenomics and Personalized Medicine